Atyr PHARMA INC (NASDAQ:ATYR – Get Free Report) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 440,900 shares, an increase of 27.1% from the August 15th total of 346,800 shares. Based on an average daily volume of 387,800 shares, the short-interest ratio is currently 1.1 days. Approximately 0.6% of the shares of the company are short sold.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Atyr PHARMA in a research report on Wednesday, August 14th. Jefferies Financial Group assumed coverage on shares of Atyr PHARMA in a report on Thursday, September 5th. They set a “buy” rating and a $9.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a research note on Thursday, August 15th.
Read Our Latest Stock Analysis on ATYR
Atyr PHARMA Stock Performance
Atyr PHARMA (NASDAQ:ATYR – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. As a group, equities research analysts predict that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.
Insider Buying and Selling at Atyr PHARMA
In related news, Director Paul Schimmel acquired 52,300 shares of the business’s stock in a transaction dated Wednesday, July 24th. The stock was acquired at an average price of $1.93 per share, with a total value of $100,939.00. Following the completion of the transaction, the director now owns 413,023 shares of the company’s stock, valued at $797,134.39. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.70% of the company’s stock.
About Atyr PHARMA
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
Featured Articles
- Five stocks we like better than Atyr PHARMA
- 3 Warren Buffett Stocks to Buy Now
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- What Are the U.K. Market Holidays? How to Invest and Trade
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- Trading Halts Explained
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.